Ketorolac Dosing Recommendations
For adults under 65 years without contraindications, administer ketorolac 20 mg PO once (following IV/IM dosing), then 10 mg every 4-6 hours as needed, not exceeding 40 mg/day; for patients ≥65 years, reduce to 10 mg PO once, then 10 mg every 4-6 hours as needed, not exceeding 40 mg/day, with total treatment duration (IV/IM plus oral) not exceeding 5 days 1.
Standard Adult Dosing (Age 17-64 Years)
The FDA-approved oral ketorolac regimen for younger adults consists of:
- Initial dose: 20 mg PO once (only as continuation after IV/IM ketorolac)
- Maintenance: 10 mg every 4-6 hours as needed
- Maximum daily dose: 40 mg/day
- Critical limitation: Do NOT shorten the 4-6 hour dosing interval 1
Important caveat: Oral ketorolac should never be used as initial therapy—it is only indicated as continuation therapy following IV or IM administration 1.
Elderly Dosing (Age ≥65 Years)
Dose reduction is mandatory in older adults due to pharmacokinetic changes:
- Initial dose: 10 mg PO once (following IV/IM dosing)
- Maintenance: 10 mg every 4-6 hours as needed
- Maximum daily dose: 40 mg/day 1
The rationale for this reduction is supported by pharmacokinetic data showing that elderly patients experience:
- 10% higher peak plasma concentrations
- 37% longer elimination half-life (4.52 vs 3.31 hours)
- 28% higher systemic exposure (AUC) 2, 3
Duration Limits: The 5-Day Rule
The combined duration of IV/IM plus oral ketorolac must not exceed 5 days in adults 1. This restriction exists because risk of serious gastrointestinal bleeding increases markedly with prolonged use, particularly in elderly patients receiving average daily doses >60 mg 1.
A large postmarketing surveillance study demonstrated dose-dependent GI bleeding risk:
- Patients <65 years on ≤60 mg/day: 0.4% incidence
- Patients ≥65 years on >120 mg/day: 7.7% incidence
- Patients ≥65 years with prior peptic ulcer disease on >120 mg/day: 25% incidence 1
Special Populations Requiring Dose Reduction
The same reduced dosing (10 mg initial, then 10 mg q4-6h, max 40 mg/day) applies to:
- Patients ≥65 years
- Patients with renal impairment
- Patients weighing <50 kg (110 lbs) 1
Absolute Contraindications
Do not use ketorolac in patients with:
- Active peptic ulcer disease (strong contraindication given case reports of bleeding even in "healed" ulcer patients 4)
- Chronic kidney disease 5
- Heart failure 5
- Severe hepatic disease
Clinical Context from Guidelines
While the FDA label provides specific dosing, geriatric pain management guidelines emphasize that NSAIDs like ketorolac should be used "rarely, and with extreme caution, in highly selected individuals" in older adults, only when safer therapies have failed 5. The guidelines recommend routine assessment for GI and renal toxicity, hypertension, and heart failure in all patients taking NSAIDs 5.
Practical Considerations
Recent evidence suggests that lower doses may be equally effective with better safety profiles. A 2025 meta-analysis found no difference in analgesic efficacy between lower and standard doses 6, and a 2021 trial showed equivalent pain relief with 10 mg, 20 mg, and 30 mg IV doses in renal colic 7. However, the FDA-approved dosing remains the standard of care until labeling changes occur.
Importantly, a 2026 retrospective study of elderly surgical patients found that single 30 mg IV doses were not associated with increased postoperative acute kidney injury 8, suggesting short-term, low-dose use may be safer than previously thought—though this doesn't change current FDA recommendations for oral dosing.
Never exceed the 4-6 hour minimum dosing interval, never exceed 40 mg/day oral dose, and never extend treatment beyond 5 days total (IV/IM + oral combined) 1.